Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
Standardized SEC financial data for TEVA PHARMACEUTICAL INDUSTRIES LTD — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000818686 · NYSE · Pharmaceutical Preparations.
Income statement
USD
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
$16.66B
$15.88B
$14.93B
$15.85B
$16.54B
$17.26B
Cost of revenue
$8.93B
$8.28B
$7.95B
$8.20B
$8.48B
$8.32B
Gross profit
$7.73B
$7.59B
$6.97B
$7.64B
$8.06B
$8.94B
R&D expense
$997.0M
$967.0M
$838.0M
$953.0M
$998.0M
$1.01B
SG&A expense
$2.50B
$2.43B
$2.27B
$2.34B
$2.54B
$2.69B
Operating income
-$3.57B
$1.72B
-$2.20B
$433.0M
-$303.0M
$2.16B
EBITDA
-$2.02B
$3.05B
-$889.0M
$1.59B
$756.0M
$3.16B
Interest expense
$901.0M
$913.0M
$948.0M
$1.08B
$1.00B
$950.0M
Pretax income
-$4.41B
$658.0M
-$3.16B
-$624.0M
-$1.28B
$1.22B
Income tax
$168.0M
$211.0M
$643.0M
$7.0M
$676.0M
$180.0M
Net income
-$3.99B
$417.0M
-$2.45B
-$559.0M
-$1.64B
$1.41B
EPS (diluted)
$-3.64
$0.38
$-2.20
$-0.50
$-1.45
$1.21
Standardized from TEVA PHARMACEUTICAL INDUSTRIES LTD's SEC filings — per-share figures split-adjusted. Full history via the API.